Comparison of two different immunosuppression protocols in highly sensitized renal transplant recipients: Campath [alemtuzumab] induction with tacrolimus monotherapy vs thymoglobulin [antithymocyte globulin] induction with triple drug protocol

Trial Profile

Comparison of two different immunosuppression protocols in highly sensitized renal transplant recipients: Campath [alemtuzumab] induction with tacrolimus monotherapy vs thymoglobulin [antithymocyte globulin] induction with triple drug protocol

Completed
Phase of Trial: Phase II

Latest Information Update: 22 May 2015

At a glance

  • Drugs Alemtuzumab (Primary) ; Tacrolimus (Primary) ; Antithymocyte globulin; Corticosteroids; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Sep 2011 Additional lead investigator identified as reported by ClinicalTrials.gov.
    • 06 Sep 2011 Planned end date changed from 1 Aug 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
    • 06 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top